Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | TRHR | P34981 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678488 | 0.85 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL678487 | 0.85 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7759091 | 0.81 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7759104 | 0.81 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1000429 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9TRHR | |
| SCHEMBL1000430 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9TRHR | |
| SCHEMBL5734357 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4595206 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4595209 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2182026 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC | 2021-07-08 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2819702-A1 | NOVEL PRODRUG CONTAINING MOLECULE COMPOSTIONS AND THEIR USES | Ambrx, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130814-A1 | NOVEL PRODRUG CONTAINING MOLECULE COMPOSTIONS AND THEIR USES | AMBRX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011133948-A2 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| CN-101795675-A | Use has the colonic delivery that the Zn/ pectin beads of Eudragit coating carries out | DA VOLTERRA | 2010-08-04 | — | — | CN | disclosed |
| US-20100160209-A1 | Composition and Method for Increasing Cell Permeability of a Compound | SMITHKLINE BEECHAM CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-6858580-B2 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | NOBEX CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040152769-A1 | Modified carbamate-containing prodrugs and methods of synthesizing same | BIOCON LIMITED (IN) | 2004-08-05 | — | — | US | disclosed |
| US-6770625-B2 | CONTAINING A FATTY ACID TO LOWER THE PRECIPITATION POINT OF BILE ACID SALT, WHICH IN TURN LOWERS THE SOLUBILITY OF THE FATTY ACID | NOBEX CORPORATION | 2004-08-03 | — | — | US | disclosed |
| WO-2004043396-A2 | MODIFIED CARBAMATE-CONTAINING PRODRUGS AND METHODS OF SYNTHESIZING SAME | NOBEX CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1404355-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | Nobex Corporation (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040017387-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith | BIOCON LIMITED (IN) | 2004-01-29 | — | — | US | disclosed |
| US-20030228275-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-12-11 | — | — | US | disclosed |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2003-04-10 | — | — | US | disclosed |
| WO-2003022210-A2 | PHARMACEUTICAL COMPOSITIONS OF DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002098446-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | DPP4 424/4885DPP8 260/4885DPP9 358/4885 |
| US-20030228275-A1 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | SI, SLC10A2, PIGO | DPP4 620/4885DPP8 425/4885DPP9 902/4885 |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | SLC10A1, SLC10A2, NR1H4 | DPP4 1015/4885DPP8 1013/4885DPP9 1451/4885 |
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | DPP4 424/4885DPP8 260/4885DPP9 358/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | DPP4 424/4885DPP8 260/4885DPP9 358/4885 |
| US-20040152769-A1 | Modified carbamate-containing prodrugs and methods of synthesizing same | DCTD, TST, CBR1 | DPP4 740/4885DPP8 538/4885DPP9 643/4885 |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | DPP4 569/4885DPP8 342/4885DPP9 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.